tradingkey.logo

CeriBell Inc

CBLL
11.385USD
+0.065+0.57%
Close 10/31, 16:00ETQuotes delayed by 15 min
416.69MMarket Cap
LossP/E TTM

CeriBell Inc

11.385
+0.065+0.57%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of CeriBell Inc

Currency: USD Updated: 2025-10-30

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. Despite a weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

CeriBell Inc's Score

Industry at a Glance

Industry Ranking
71 / 210
Overall Ranking
156 / 4621
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 8 analysts
Strong Buy
Current Rating
29.667
Target Price
+146.61%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

CeriBell Inc Highlights

StrengthsRisks
Ceribell, Inc. is a commercial-stage medical technology company. It is focused on transforming the diagnosis and management of patients with serious neurological conditions. It has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable and rapidly deployable hardware with sophisticated artificial intelligence (AI)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. Point-of-Care EEG enables early detection and management of suspected seizure patients, promoting precise patient care and hospital-wide efficiencies. Its Clarity AI algorithm interprets EEG in real-time, provides bedside alerts and continuous monitoring for status epilepticus. The Ceribell EEG Portal makes it easy to remotely review EEG in real-time with pre-annotated EEG insights.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 152.47% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 65.44M.
Overvalued
The company’s latest PE is -8.40, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 30.96M shares, increasing 10.03% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 1.10K shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-30

The company's current financial score is 7.67, which is higher than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 21.20M, representing a year-over-year increase of 38.42%, while its net profit experienced a year-over-year increase of 52.59%.

Score

Industry at a Glance

Previous score
7.67
Change
0

Financials

8.07

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data

Quality of Earnings

7.18

Operational Efficiency

8.04

Growth Potential

7.80

Shareholder Returns

7.26

CeriBell Inc's Company Valuation

Currency: USD Updated: 2025-10-30

The company’s current valuation score is 7.26, which is higher than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -8.40, which is -0.18% below the recent high of -8.39 and -238.66% above the recent low of -28.46.

Score

Industry at a Glance

Previous score
7.26
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 71/210
No Data

Earnings Forecast

Currency: USD Updated: 2025-10-30

The company’s current earnings forecast score is 9.14, which is higher than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for CeriBell Inc is 31.00, with a high of 36.00 and a low of 19.00.

Score

Industry at a Glance

Previous score
9.14
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 8 analysts
Strong Buy
Current Rating
29.667
Target Price
+162.07%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

89
Total
4
Median
7
Average
Company name
Ratings
Analysts
Ceribell Inc
CBLL
8
Boston Scientific Corp
BSX
36
Edwards Lifesciences Corp
EW
35
Intuitive Surgical Inc
ISRG
34
Veeva Systems Inc
VEEV
33
Thermo Fisher Scientific Inc
TMO
30
1
2
3
...
18

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-30

The company’s current price momentum score is 5.94, which is lower than the Healthcare Equipment & Supplies industry's average of 6.55. Sideways: Currently, the stock price is trading between the resistance level at 13.03 and the support level at 10.44, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
6.27
Change
-0.33

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(2)
Neutral(2)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.329
Neutral
RSI(14)
39.210
Neutral
STOCH(KDJ)(9,3,3)
9.362
Oversold
ATR(14)
0.642
Low Volatility
CCI(14)
-195.803
Sell
Williams %R
92.481
Oversold
TRIX(12,20)
0.185
Sell
StochRSI(14)
6.384
Oversold
Moving Average
Sell(6)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MA5
12.094
Sell
MA10
12.557
Sell
MA20
12.487
Sell
MA50
12.085
Sell
MA100
13.873
Sell
MA200
16.688
Sell

Institutional Confidence

Currency: USD Updated: 2025-10-30

The company’s current institutional recognition score is 7.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.43. The latest institutional shareholding proportion is 84.45%, representing a quarter-over-quarter decrease of 6.54%. The largest institutional shareholder is The Vanguard, holding a total of 1.33M shares, representing 3.61% of shares outstanding, with 86.14% increase in holdings.

Score

Industry at a Glance

Previous score
7.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
Fidelity Management & Research Company LLC
4.69M
-1.32%
TPG Capital, L.P.
3.97M
--
Longitude Capital Management Co., LLC
2.48M
--
Ally Bridge Group (HK) Limited
2.44M
+12.18%
Global Value Investment Portfolio Management Pte. Ltd.
2.37M
--
Red Tree Management, LLC
2.21M
--
Parvizi (Josef)
2.09M
+0.32%
BlackRock Institutional Trust Company, N.A.
1.37M
+75.05%
The Vanguard Group, Inc.
Star Investors
1.33M
+90.98%
Chao (Xingjuan)
1.10M
-0.26%
1
2

Risk Assessment

Currency: USD Updated: 2025-10-30

The company’s current risk assessment score is 4.34, which is lower than the Healthcare Equipment & Supplies industry's average of 4.57. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
4.34
Change
0
Beta vs S&P 500 index
--
VaR
--
240-Day Maximum Drawdown
+63.13%
240-Day Volatility
+71.26%

Return

Best Daily Return
60 days
+7.04%
120 days
+7.71%
5 years
--
Worst Daily Return
60 days
-15.25%
120 days
-15.25%
5 years
--
Sharpe Ratio
60 days
-1.59
120 days
-1.25
5 years
--

Risk Assessment

Maximum Drawdown
240 days
+63.13%
3 years
--
5 years
--
Return-to-Drawdown Ratio
240 days
-0.94
3 years
--
5 years
--
Skewness
240 days
-1.02
3 years
--
5 years
--

Volatility

Realised Volatility
240 days
+71.26%
5 years
--
Standardised True Range
240 days
+9.47%
5 years
--
Downside Risk-Adjusted Return
120 days
-168.38%
240 days
-168.38%
Maximum Daily Upside Volatility
60 days
+39.04%
Maximum Daily Downside Volatility
60 days
+35.21%

Liquidity

Average Turnover Rate
60 days
+0.91%
120 days
+0.90%
5 years
--
Turnover Deviation
20 days
--
60 days
--
120 days
--

Peer Comparison

Healthcare Equipment & Supplies
CeriBell Inc
CeriBell Inc
CBLL
7.16 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cencora Inc
Cencora Inc
COR
8.59 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Boston Scientific Corp
Boston Scientific Corp
BSX
8.51 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Artivion Inc
Artivion Inc
AORT
8.50 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Hologic Inc
Hologic Inc
HOLX
8.47 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
Lantheus Holdings Inc
LNTH
8.34 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI